Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00622401 · ClinicalTrials.gov registry record · Phase 1
Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12
A Phase 1 study, sponsored by Beth Israel Deaconess Medical Center.
- Terminated
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT00622401 is a Phase 1 study that was terminated before completion, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 8 participants.
The verdict
NCT00622401, a Phase 1 study, was terminated before completion, sponsored by Beth Israel Deaconess Medical Center.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor Fusion vaccine given with IL-12 for patients with breast cancer. RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor cells. Interleukin-12 may stimulate the white blood cells to kill tumor cells. Giving vaccine therapy together with interleukin-12 may kill more tumor cells. PURPOSE: This phase I/II trial is studying the side effects and best dose of interleukin-12 when given together with vaccine therapy and to see how well they work in treating women with stage IV breast cancer.
Interventions
- BIOLOGICAL Dendritic Cell/Tumor Fusion Vaccine
- DRUG Interleukin-12
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2009-12 |
| Est. Completion | 2014-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00622401
The ClinicalTrials.gov registry entry for NCT00622401 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Beth Israel Deaconess Medical Center, which has 488 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Dendritic Cell/Tumor Fusion Vaccine is the first listed.
NCT00622401 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00622401 about?
NCT00622401 is a clinical study titled "Vaccination of Patients With Breast Cancer With Dendritic Cell/Tumor Fusions and IL-12". The purpose of this study is to test the safety of an investigational Dendritic Cell/Tumor Fusion vaccine given with IL-12 for patients with breast cancer. RATIONALE: Vaccines made from a person's tumor cells and white blood cells may help the body build an effective immune response to kill tumor c...
What is the current status of trial NCT00622401?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2009-12. Estimated completion is 2014-10.
What interventions are being tested in trial NCT00622401?
The interventions under investigation include: Dendritic Cell/Tumor Fusion Vaccine (BIOLOGICAL), Interleukin-12 (DRUG).
Who is sponsoring clinical trial NCT00622401?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.